title: [Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
abstract: It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors. The patient (75 years old) at the decompensation of chronic heart failure in the background of persistent atrial fibrillation was appointed the combination of ACE inhibitors, spironolactone, and dabigatran. 10 days after the start of using spironolactone and dabigatran bleeding was marked with decrease in hemoglobin levels to 69 g/l, creatinine level increases to 3.6 mg/dL (glomerular filtration rate by MDRD 18 ml/min/1,73 m2), and potassium to 5.5 mEq/ l. Against the background of the abolition of drugs normalization of renal function was marked. The question of an increased risk of nephrotoxicity with concurrent use of ACE inhibitors and spironolactone is discussed.
authors.forename: D A
authors.initials: DA
authors.lastname: Andreev
authors.forename: Z K
authors.initials: ZK
authors.lastname: Gappoeva
authors.forename: D A
authors.initials: DA
authors.lastname: Sychev
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Giliarov
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000009:adverse effects; D000069604:Dabigatran; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000379:methods; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy; D006470:Hemorrhage / Q000139:chemically induced / Q000628:therapy; D006801:Humans; D008297:Male; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000188:drug therapy; D013148:Spironolactone / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D028761:Withholding Treatment; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D002317:Cardiovascular Agents; D015091:beta-Alanine; D013148:Spironolactone; D000069604:Dabigatran